(Botulinum toxin and instillations)
Intravesical treatments allow treating various functional urinary pathologies. It includes the administration of botulinum toxin, that enables the treatment of urinary incontinence associated with micturition urgency, via minimally invasive therapy. Botulinum toxin is also used in other urological disorders, such as certain bladder pain syndromes.
On the other hand, intravesical therapy is effective in the treatment of bladder pathologies associated to pain and inflammatory conditions at this level, with the intention of helping to regenerate the protective layer of the bladder mucosa, which can be affected by different infectious and inflammatory processes.
Overactive bladder syndrome: is characterised by the urgency, with or without urge urinary incontinence, usually with an increased daytime urination frequency and nocturia, and in the absence of infection or any other obvious pathology.
Overactive bladder is classified as neurogenic (NOB) when there is an identified neurological disease, being frequent causes: Parkinson’s, multiple sclerosis, spinal cord injuries or strokes, among others. NOB has an overall prevalence of 12-19%, placing an enormous burden on the healthcare system, the society, and the quality of life of the affected individuals. In urology, the use of onabotulinumtoxinA has been widely evaluated in patients with NOB.